Hôpital René Huguenin

Recent papers from Hôpital René Huguenin

1. Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trialThe Lancet · 2025
2. Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trialTranslational Oncology · 2026
3. 527P Title results of the safety run-in part of the TUC-TOC phase II trial (NCT05955170): Tucatinib in combination with oral etoposide (VP16) - trastuzumab in patients with metastatic HER2-positive breast cancer (HER2+ mBC)ESMO Open · 2026
4. 443P Assessment of maintenance by endocrine therapies for metastatic breast cancer in a multicenter national observational studyESMO Open · 2026
5. 449P Impact of a previous malignancy on the presentation and outcomes of metastatic breast cancer: A nationwide ESME studyESMO Open · 2026
6. Advancing equitable access to innovation in breast cancernpj Breast Cancer · 2025
7. Prognostic Value of a Joint K‐PD Model With Tumor Size Dynamics and CA‐125 Kinetics in Recurrent Ovarian Cancer Patients: BOLD Phase II GINECO StudyCPT Pharmacometrics & Systems Pharmacology · 2025
8. Expression of interleukin-18 in primary Sjögren syndrome and its potential mechanisms with disease: A systematic review and meta-analysisMedicine · 2025
9. Screening Mammography and Breast Cancer: Variation in Risk with Rare Deleterious or Predicted Deleterious Variants in DNA Repair GenesCancers · 2025
10. Explaining the Relationships Between Age, Endocrine Therapy Persistence, and Risk of Recurrence in Hormone Receptor–Positive Early Breast Cancer: A Nationwide Cohort StudyJournal of Clinical Oncology · 2025
11. Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical StudyCancer Research Communications · 2025
12. An international Phase IV field study - psychometric properties of the updated module on assessing quality of life of patients with breast cancer EORTC QLQ-BR42The Breast · 2025
13. Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysisJournal of Gynecologic Oncology · 2025
14. Resveratrol-coated gold nanorods produced by green synthesis with activity against Candida albicansVirulence · 2024
15. Metabolic regulation of the immune system in health and diseases: mechanisms and interventionsSignal Transduction and Targeted Therapy · 2024
16. The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker researchMolecular Cancer · 2024
17. High-dose chemotherapy with autologous haematopoietic stem cell transplantation in patients with isolated vitreoretinal lymphoma: A LOC network study2024
18. 179O Combination of olaparib, durvalumab and fulvestrant in patients with advanced ER-positive, HER2-negative breast cancer harboring homologous recombination repair (HRR) deficiency or microsatellite instability (MSI): Results of the international phase II DOLAF trialESMO Open · 2024
19. 268MO Safety of vaginal estrogen therapy after early-stage breast cancer: A nationwide population-based target trial emulationESMO Open · 2024
20. 270MO An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: Results of the validation study phase IV EORTC QLQ-BR42ESMO Open · 2024